Research with BPH patients indicated that there was a need for clear, concise information that would help men better understand their BPH symptoms. The Matter of FACT™ basics is a free patient support program that Boehringer Ingelheim has developed to address this need. The program provides a resource for facts about male urinary symptoms associated with BPH and detailed information about FLOMAX for patients and their loved ones.
Registered members of the Matter of FACT™ basics:
- Have access to free downloadable educational materials about BPH and FLOMAX
- Receive ongoing communications encouraging them to speak to their physician about their male urinary symptoms and available treatment options
- Get rebates and other special offers
- Can sign up for a free prescription refill reminder service to promote adherence
Registration is simple and requires only minimal information from patients. Patients identify themselves as diagnosed with BPH, undiagnosed but experiencing urinary problems or current FLOMAX users, and all information they receive is tailored to their needs.
Visit the Matter of FACT™ basics section of www.4FLOMAX.com to learn more.
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid driving or hazardous tasks for 12 hours after their first dose or increase in dose should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
† Comparison based on the branded alpha-blockers Cardura®, FLOMAX, Hytrin®, Minipress®, and Uroxatral®.
1. Verispan's Managed Care Formulary Drug Audit, Spring 2005. The spring 2005 data represent an estimated 58% of all US HMO subscribers whose prescriptions benefits are controlled by formularies.
All registered trademarks are owned by their respective companies.
